News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CARSGEN-B (02171.HK) Once Tumbles 36% to Hit New Low; Drug Put on Clinical Hold by US FDA
CARSGEN-B (02171.HK) was under hefty selling this morning (13th). The stock opened 14.9% lower before its losses expanded sharply in the early session, and plunged 35.7% to a low o...
Reset
Send
The window will close in 5 seconds
CARSGEN-B (02171.HK) Once Tumbles 36% to Hit New Low; Drug Put on Clinical Hold by US FDA
Close
Recommend
3
Positive
5
Negative
4
 
SHORT SELL
 
STOCK INFO

CARSGEN-B (02171.HK)  +0.180 (+1.463%)    Short selling $8.28M; Ratio 16.680%   was under hefty selling this morning (13th). The stock opened 14.9% lower before its losses expanded sharply in the early session, and plunged 35.7% to a low of $6.07, a new listing low. It last printed at $6.76, down 28.39%. Volume surged to 7.5013 million shares, involving $50.6818 million.

CARsgen Therapeutics, CARSGEN-B's subsidiary in the US, received a notice from the US Food and Drug Administration (FDA) to the effect that CT053, CT041 and CT071 be put on clinical hold pending resolution of the findings following an inspection of the manufacturing site located in Durham, North Carolina, due to issues related to CMC (chemistry, manufacturing and controls processes in the development, licensure, manufacturing, and ongoing marketing of pharmaceutical products), according to the Company's announcement.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-03-21 16:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.